LON:CLBX - Cellbxhealth PLC
Executive Summary
Cellbxhealth PLC is a Healthcare company in the Medical - Diagnostics & Research industry, listed on LON under CLBX and reporting in GBX. It provides precision circulating tumour cell intelligence solutions for research and drug development, with revenue derived from product sales and biopharma services.
The investment case requires commercial traction to translate into sustained growth, particularly from the US pharma statement of work worth 65,000 US dollars and higher revenue targets for 2026 and 2027. The key near-term catalyst is execution against those raised targets, with the timing of further commercial validation dependent on future contract awards and reported results; the primary risk is that the FY2025 revenue shortfall and limited biopharma activity indicate continued execution and cash-runway risk.
OPPORTUNISTIC BUY. Conviction Score: 59/100. A sustained recovery in revenue, delivery of larger contracts and evidence that biopharma services can scale would strengthen the case, while renewed guidance reductions, contract losses or a dilutive financing would change the view.
Business Model
Cellbxhealth generates revenue through product sales and biopharma services. In FY2025, total revenue was GBP 1.4 million, comprising GBP 1.1 million from products and GBP 0.3 million from biopharma services; total revenue fell from GBP 2.9 million in FY2024, partly because approximately GBP 0.2 million of sales were deferred into Q1 2026.
Customers include pharmaceutical companies, biotechnology companies and research organisations that use circulating tumour cell analysis in drug development and research workflows. The 65,000 US dollar US pharma statement of work demonstrates contract-based demand, but the business remains highly dependent on converting a small number of commercial relationships into recurring, larger revenue streams.
Its proposed competitive advantage is specialist expertise in precision circulating tumour cell intelligence, supported by its cell-analysis technology and technical know-how. However, the available evidence does not establish a quantified moat: FY2025 revenue declined materially, biopharma revenue remained limited at GBP 0.3 million, and reported revenue was below prior guidance of GBP 1.6 million.
Cost reductions are an important operating lever in the current recovery strategy, but they should not be confused with demonstrated operating leverage. Revenue scale, gross-margin disclosure and contract renewal rates are not provided in the research, limiting confidence in the sustainability of profitability and cash generation.
Financial Snapshot
Recent Catalysts
[16 January 2026] - Cellbxhealth released preliminary fourth-quarter and FY2025 results, reporting revenue of GBP 1.4 million against GBP 2.9 million in FY2024. Approximately GBP 0.2 million of sales were deferred into Q1 2026, and revenue split between GBP 1.1 million of product sales and GBP 0.3 million of biopharma services. Source: Preliminary Fourth Quarter 2025 Financial Results, regulatory announcement.
[16 January 2026] - The preliminary results showed that FY2025 revenue fell below prior guidance of GBP 1.6 million, highlighting a significant commercial shortfall despite the proposed cost savings and raised forward revenue targets. Source: Preliminary Fourth Quarter 2025 Financial Results, regulatory announcement.
[25 November 2025] - Cellbxhealth announced a new commercial development that formed part of its improving commercial momentum. The available public listing does not provide enough detail to confirm the contract value, customer or revenue contribution, so no further terms are assumed. Source: London Stock Exchange company news page.
[16 January 2026] - Cellbxhealth indicated that approximately GBP 0.2 million of FY2025 sales moved into Q1 2026, providing a specific near-term revenue bridge but also demonstrating the importance of timing and customer spending decisions. Source: Preliminary Fourth Quarter 2025 Financial Results, regulatory announcement.
Thesis Evaluation
Bull Case (25% weight)
The 65,000 US dollar US pharma statement of work converts into repeat business, additional contracts materially increase recurring revenue, and raised 2026 and 2027 targets are met or exceeded. Revenue growth offsets the smaller FY2025 base while cost savings preserve liquidity, supporting a 12-month target of 1.20p.
Base Case (50% weight)
Commercial activity recovers gradually from the GBP 1.4 million FY2025 revenue base, with the deferred GBP 0.2 million contributing in Q1 2026 and the US pharma contract supporting a modest improvement in biopharma services. Cost containment limits cash burn, but execution remains insufficient for a sustained re-rating, supporting a 12-month target of 0.75p.
Bear Case (25% weight)
The US pharma contract does not generate repeat work, deferred sales fail to convert into recognised revenue, and limited biopharma traction leaves FY2025's revenue decline unresolved. Further guidance reductions, cash consumption or dilutive financing could force a substantial discount, implying a 12-month target of 0.30p.
Key Risks
- Revenue recovery falls short: FY2025 revenue of GBP 1.4 million was below prior guidance of GBP 1.6 million and materially below GBP 2.9 million in FY2024, indicating that raised 2026 and 2027 targets may not be achieved. Estimated probability: 40%. Impact: severe.
- Contract concentration and limited repeat revenue: The 65,000 US dollar US pharma statement of work may not lead to repeat awards or material expansion, leaving Cellbxhealth dependent on a limited number of research and biopharma customers. Estimated probability: 35%. Impact: moderate.
- Minimal biopharma traction: Biopharma services contributed only GBP 0.3 million of FY2025 revenue, so the higher-value commercial offering has yet to demonstrate scale. Estimated probability: 45%. Impact: moderate.
- Cash runway and financing risk: Continued revenue underperformance may increase cash burn and create a need for additional funding before the operating recovery is established. Estimated probability: 35%. Impact: severe.
- Liquidity and market-price volatility: The current 0.59p share price is close to the 52-week low of 0.53p and remains 76.8% below the 52-week high of 2.8p, indicating both limited liquidity and substantial potential volatility. Estimated probability: 45%. Impact: moderate.
- Competitive differentiation is unproven: The available disclosures do not quantify a durable competitive moat or recurring-revenue retention rate, leaving Cellbxhealth exposed to liquid-biosphy competitors and customers' alternative testing approaches. Estimated probability: 40%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: speculative investors with a high risk tolerance who can tolerate a multi-year holding period, potential dilution and sharp drawdowns in a 0.59p AIM-quoted Healthcare security; the position is appropriate only for investors able to size the holding as high-risk and monitor revenue guidance, contract conversion and cash consumption closely.
Avoid if: investors require recurring revenue, demonstrated profitability, a broad institutional shareholder base or dependable liquidity should not own Cellbxhealth because the FY2025 revenue decline, GBP 0.3 million biopharma contribution, limited customer diversification and the share price's proximity to its 52-week low create substantial execution and financing risk.
Recommendation
OPPORTUNISTIC BUY - 59/100 - The tier reflects improving commercial evidence from the 65,000 US dollar US pharma statement of work, deferred FY2025 sales and cost reductions, balanced against the FY2025 revenue miss and limited biopharma traction. The call would be upgraded if Cellbxhealth delivers the raised 2026 and 2027 revenue targets, wins repeat or larger contracts and demonstrates improving cash generation. It would be degraded by another revenue or guidance reduction, failure to convert the deferred sales, cancellation of material contracts or a dilutive capital raise. Position sizing should reflect the high volatility and execution risk inherent in the shares. At the current price of 0.65p the shares trade above our buy ceiling of 0.45p: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is 0.75p, 15% above the current price of 0.65p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below 0.45p - below this level the upside to the base-case target (0.75p) is at least 2x the downside to the bear case (0.30p), the minimum risk/reward we require before committing new capital.
between 0.45p and 0.75p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above 0.75p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if the thesis is invalidated by a material contract loss, FY2026 revenue guidance being reduced or materially missed, biopharma revenue failing to expand materially from the FY2025 base, or a dilutive equity raise before the commercial recovery is established, regardless of price - the bear target of 0.30p is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Flat.
| Report date | Conviction |
|---|---|
| 2026-11-14 | 59 |
| 2026-10-28 | 59 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public company announcements, regulatory announcements, preliminary financial results, London Stock Exchange company news, public web research and general analyst commentary.
Primary source types: Preliminary Fourth Quarter 2025 Financial Results, regulatory announcements, company investor relations materials and exchange market-data disclosures.
Key sources
- Cellbxhealth PLC Share Price (LSE:CLBX) | AJ Bell
- CelLBxHealth (CLBX) Accelerates Cost Reduction ...
- Cellbxhealth PLC, CLBX:LSE summary - FT.com
- Cellbxhealth Share Price | CLBX Stock - Investing.com UK
- Angle Share Price | LON CLBX Stock - Investing.com AU
- CelLBxHealth plc (CLBX) Issues Q3 2026 Trading Update, Raises FY 2026 Revenue Guidance to GBP 1.8 Million and Projects GBP 3.0 - GBP 4.0 Million for FY
- CelLBxHealth plc (CLBX) Reports Q3 2026 Trading Update ...
- CelLBxHealth lands contract with Swiss biotech for clinical study
- Angle Stock Price Today | LON: CLBX Live - Investing.com
- Company Summary
Analysis generated 2026-10-28. Market data as of 2026-11-13.